Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 22.09% | -67.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.09% | -67.65% | |||
| Cost of Revenue | 433.33% | -63.22% | |||
| Gross Profit | -497.37% | -71.92% | |||
| SG&A Expenses | -15.29% | 3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.97% | -45.37% | |||
| Operating Income | -17.33% | 38.93% | |||
| Income Before Tax | -16.60% | -21.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.62% | -21.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.62% | -21.70% | |||
| EBIT | -17.33% | 38.93% | |||
| EBITDA | -17.93% | 25.25% | |||
| EPS Basic | -9.24% | -17.71% | |||
| Normalized Basic EPS | 8.15% | 36.94% | |||
| EPS Diluted | -9.24% | -17.71% | |||
| Normalized Diluted EPS | 8.15% | 36.94% | |||
| Average Basic Shares Outstanding | 6.76% | 3.38% | |||
| Average Diluted Shares Outstanding | 6.76% | 3.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||